Lapatinib (Tyverb) in combination with an aromatase inhibitor for the indication metastatic HR+ HER2+ breast cancer

For postmenopausal patients with HR+ HER2+ metastatic breast cancer without rapid progression, without extensive visceral metastases and without brain metastases, primary care treatment with lapatinib in combination with an aromatase inhibitor has a therapeutic value equal to that of trastuzumab in combination with an aromatase inhibitor.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.